©2024 Stanford Medicine
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Not Recruiting
Trial ID: NCT01020305
Purpose
This study evaluates if temsirolimus causes a reduction in the serum levels of
prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer
(CRPC).
Official Title
Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
INCLUSION CRITERIA
- Histologically-confirmed adenocarcinoma of the prostate, characterized as symptomatic
castration-resistant prostate cancer (CRPC)
- Serum PSA ≥ 2 ng/mL
- Rising PSA on 3 consecutive occasions at least 1 week apart (not limited to the 30-day
screening period)
- Failure of bilateral orchiectomy and/or therapy with an LHRH agonist and bicalutamide
- Castrate level of testosterone (< 50 ng/dL)
- Currently being treated with bicalutamide
- No prior antiandrogen therapy except bicalutamide
- Age ≥ 18 years
- Life expectancy > 6 months
- Performance status
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- OR
- Karnofsky performance status ≥ 80%
- Ability to understand and the willingness to sign a written informed consent
EXCLUSION CRITERIA
- Radiotherapy for prostate cancer within 28 days prior to Day 1, except single-fraction
radiotherapy for pain control
- Prior treatment with mTOR inhibitors
- Prior treatment with chemotherapy for prostate cancer
- Symptomatic bone metastases (ie, asymptomatic bone metastases are eligible)
- Visceral metastases
- Absolute neutrophil count (ANC) < 1500/uL
- Platelet count ≤ 100 x 10e9/L
- Total bilirubin ≥ 1.5 x Upper Limit of Normal (ULN)
- Alkaline phosphatase > 2.5 x ULN
- AST > 2.5 x ULN
- ALT > 2. 5x ULN
- Serum creatinine > 2.0 mg/dL
- Hemoglobin < 9 g/dL
- Men with reproductive potential who do not agree to use an accepted and effective
method of contraception during the study treatment period and for at least 3 months
after completion of the study treatment
- History of other malignancies within 5 years except for tumors with a negligible risk
for metastasis or death, such as adequately-controlled basal cell carcinoma,
squamous-cell carcinoma of the skin, or early-stage bladder cancer
- Participation in another experimental drug study either planned or within 4 weeks of
the first study treatment
- Persistent Grade ≥ 1 AEs due to prior drug therapy, including investigational drugs,
administered more than 14 days before study enrollment
- Previously treated or other known brain metastases
- Ongoing or active infection
- Symptomatic congestive heart failure, New York Heart Association Grade II or greater
- Unstable angina pectoris
- Cardiac arrhythmia
- Significant vascular disease (eg, aortic aneurysm, aortic dissection)
- Symptomatic peripheral vascular disease
- Psychiatric illness/social situations that would limit compliance with study
requirements
- Other uncontrolled intercurrent illness
- Known to be positive for the human immunodeficiency virus (HIV) infection and
receiving antiretroviral therapies (HIV positive not requiring antiretroviral therapy
iseligible if all other entry criteria are meet)
- Inability to comply with study and/or follow-up procedures
Intervention(s):
drug: Temsirolimus
drug: Casodex (bicalutamide)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Haas
6507361252